CLINICAL TRIALS PROFILE FOR FILGOTINIB

Clinical Trials for Filgotinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02065700 ↗	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients	Active, not recruiting	Gilead Sciences	Phase 2	The primary objective of the study is to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants will be enrolled in this open-label long-term follow-up study after they have completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) or GLPG0634-CL-204 (DARWIN2), and will be evaluated for any side effects that may occur (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants will also be examined for long-term effects of filgotinib administration on disease activity (efficacy), subjects' disability, fatigue, and quality of life.
NCT02065700 ↗	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients	Active, not recruiting	Galapagos NV	Phase 2	The primary objective of the study is to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants will be enrolled in this open-label long-term follow-up study after they have completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) or GLPG0634-CL-204 (DARWIN2), and will be evaluated for any side effects that may occur (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants will also be examined for long-term effects of filgotinib administration on disease activity (efficacy), subjects' disability, fatigue, and quality of life.
NCT02873936 ↗	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	Completed	Galapagos NV	Phase 3	The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
NCT02873936 ↗	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	Completed	Gilead Sciences	Phase 3	The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Clinical Trial Conditions for Filgotinib

Condition Name

Condition Name
Intervention	Trials
Rheumatoid Arthritis	14
Ulcerative Colitis	8
Psoriatic Arthritis	5
Ankylosing Spondylitis	4

Condition MeSH

Condition MeSH
Intervention	Trials
Arthritis, Rheumatoid	16
Arthritis	16
Colitis, Ulcerative	8
Arthritis, Psoriatic	6

Clinical Trial Locations for Filgotinib

Trials by Country

Trials by Country
Location	Trials
United States	337
Australia	36
Poland	22
Canada	22
Hungary	21

Trials by US State

Trials by US State
Location	Trials
Texas	20
Florida	20
North Carolina	16
California	16
Michigan	15

Clinical Trial Progress for Filgotinib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	16
RECRUITING	8
Active, not recruiting	6

Clinical Trial Sponsors for Filgotinib

Sponsor Name

Sponsor Name
Sponsor	Trials
Galapagos NV	30
Gilead Sciences	27
Alfasigma S.p.A.	3

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	63
Other	12
UNKNOWN	2